PRESS RELEASE published on 06/13/2025 at 01:25, 7 months 26 days ago Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy FDA Approval Moderna RSV Vaccine Phase 3 Study MRESVIA
BRIEF published on 06/11/2025 at 13:05, 7 months 28 days ago Moderna to Present at Barclays Science Call Series MRNA Technology Presentation Moderna Barclays Investor Event
BRIEF published on 06/11/2025 at 13:05, 7 months 28 days ago Moderna participera à la série d'appels scientifiques de Barclays Presentation Barclays Moderne Événement Pour Les Investisseurs Technologie De L'ARNm
PRESS RELEASE published on 06/11/2025 at 13:00, 7 months 28 days ago Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 Moderna, Inc. announces participation in Barclays Speaking the Science Call Series on June 16th at 10:00am ET. Webcast available on Moderna's website Webcast MRNA Medicine Moderna Barclays Investor Event
BRIEF published on 05/31/2025 at 06:21, 8 months 9 days ago Moderna's mNEXSPIKE COVID-19 Vaccine Secures FDA Approval FDA Approval COVID-19 Vaccine Clinical Trial Moderna MNEXSPIKE
BRIEF published on 05/31/2025 at 06:21, 8 months 9 days ago Le vaccin mNEXSPIKE de Moderna contre la COVID-19 obtient l'approbation de la FDA Essai Clinique Approbation De La FDA Moderne Vaccin Contre Le Covid-19 MNEXSPIKE
PRESS RELEASE published on 05/31/2025 at 06:16, 8 months 9 days ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna's mNEXSPIKE, a new COVID-19 vaccine, receives FDA approval for high-risk age groups. The vaccine shows higher efficacy compared to the original mRNA-1273. Safety profile similar to Spikevax FDA Approval COVID-19 Vaccine Moderna Efficacy MNEXSPIKE
BRIEF published on 05/29/2025 at 00:05, 8 months 11 days ago Moderna Reports Progress and Setback in Avian Flu Vaccine Program Moderna Vaccine Development Phase 1/2 Study H5 Avian Flu MRNA-1018
BRIEF published on 05/29/2025 at 00:05, 8 months 11 days ago Moderna fait état de progrès et de revers dans son programme de vaccination contre la grippe aviaire Développement De Vaccins Moderne Étude De Phase 1/2 Grippe Aviaire H5 ARNm-1018
PRESS RELEASE published on 05/29/2025 at 00:00, 8 months 11 days ago Moderna Announces Update on Investigational Pandemic Influenza Program Moderna's Phase 1/2 H5 avian flu vaccine study shows positive interim results with robust immune response. HHS terminates late-stage development award Moderna Phase 1/2 Study Avian Flu Vaccine H5 Subtype HHS Termination
Published on 02/09/2026 at 15:00, 2 hours 9 minutes ago Gungnir Resources Inc. Announces Management And Board Changes
Published on 02/09/2026 at 14:15, 2 hours 54 minutes ago White Gold Corp. Appoints Seasoned Mining Executive Donovan Pollitt as Strategic Advisor
Published on 02/09/2026 at 14:00, 3 hours 9 minutes ago Geophysics Converge Ahead of Colosseum Deeper Drill Program
Published on 02/09/2026 at 13:00, 4 hours 9 minutes ago Eagle Plains' Partner Refined Energy Corp. Mobilizes Geophysical Team to the Dufferin West Project, Saskatchewan
Published on 02/09/2026 at 15:58, 1 hour 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: Just Group plc
Published on 02/09/2026 at 15:47, 1 hour 22 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 02/09/2026 at 15:45, 1 hour 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
Published on 02/09/2026 at 15:43, 1 hour 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Published on 02/09/2026 at 14:49, 2 hours 20 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/09/2026 at 10:40, 6 hours 29 minutes ago Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 02/09/2026 at 08:30, 8 hours 39 minutes ago THERMADOR GROUPE : Plan to separate the roles of chairman and chief executive officer
Published on 02/09/2026 at 08:30, 8 hours 39 minutes ago THERMADOR GROUPE : Projet de séparation des mandats de président et directeur général
Published on 02/09/2026 at 08:00, 9 hours 9 minutes ago Eiffage renforce son expertise dans le secteur du froid industriel avec une prise de participation majoritaire dans l’entreprise française Quercy Réfrigération
